Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JAB-8263 in advanced solid tumors
NCT04587479Phase 1Completed
- Sponsor
- Jacobio Pharmaceuticals
- Start
- Nov 2020
- Primary completion
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of jab-8263 in solid tumor, sponsored by Jacobio Pharmaceuticals. Primary endpoints: Dose Limiting Toxicities at 2.5 years and Recommended Phase 2 Dose at 2.5 years. Started Nov 2020; status: completed.
02
Drugs
jab-8263
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT04587479.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04587479.